Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Osteoporosis International

• Publication date

  1994-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF01623227PMID 8003844
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synthetic human calcitonin in postmenopausal osteoporosis: A placebo-controlled, double-blind study

  2007cited by this paper
• The use of bisphosphonates in the treatment of osteoporosis

  2005influential reference
• The use of bisphosphonates in the treatment of osteoporosis.

  1992cited by this paper
• Effects of 4‐amino‐1‐hydroxybutylidene bisphosphonate on bone biomechanics in rats

  1992cited by this paper
• Effect of a single infusion of aminohydroxypropylidene on calcium and bone metabolism in healthy volunteers monitored during 2 months.

  1991cited by this paper
• Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis

  1991influential reference
• Effect of cyclical therapy with phosphorus and etidronate on axial bone mineral density in postmenopausal osteoporotic women

  1991cited by this paper
• A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis

  1991influential reference
• Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis.

  1991cited by this paper
• Bisphosphonates

  1991cited by this paper
• Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy.

  1990cited by this paper
• Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.

  1990cited by this paper
• Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.

  1990cited by this paper
• Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.

  1990cited by this paper
• Effects of cyclical therapy for osteoporosis using an oral regimen of inorganic phosphate and sodium etidronate: a clinical and bone histomorphometric study.

  1989cited by this paper
• Effect of etidronate disodium on bone turnover following surgical menopause

  1989cited by this paper
• Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD.

  1989influential reference
• Prevention of postmenopausal bone loss by tiludronate

  1989cited by this paper
• A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone.

  1988cited by this paper
• Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis.

  1988cited by this paper
• Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).

  1988cited by this paper
• Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study.

  1987cited by this paper
• A single‐day treatment of tumor‐induced hypercalcemia by intravenous amino‐hydroxypropylidene bisphosphonate

  1986cited by this paper
• Long-term estrogen replacement therapy prevents bone loss and fractures.

  1985cited by this paper
• Long-Term Estrogen Replacement Therapy Prevent Bone Loss and Fractures

  1985cited by this paper
• Letter: Screening for breast cancer.

  1976cited by this paper
• Modifications of a specific assay for hydroxyproline in urine.

  1967cited by this paper

• The Conundrum of Medical Fracture Prevention in Chronic Kidney Disease—Summary of the Evidence and Pragmatic Clinical Guidance

  2025cites this paper
• Bisphosphonate nephropathy: A case series and review of the literature

  2021cites this paper
• Application of cyanobacteria for chiral phosphonate synthesis

  2015cites this paper
• Differential Treatment of Osteoporosis with Medicaments

  2015influential citation
• Triarylborane-dipyrromethane conjugates bearing dual receptor sites: the synthesis and evaluation of the anion binding site preference.

  2014cites this paper
• Tratamiento de la osteoporosis en pacientes de alto riesgo: El manejo del internista

  2013cites this paper
• Nutraceuticals for older people: facts, fictions and gaps in knowledge.

  2013cites this paper
• Mécanismes d'adsorption du risédronate par des phosphates de calcium biologiques: applications aux biomatériaux

  2011cites this paper
• Rheumatoid arthritis: biologicals and bone

  2011cites this paper
• Intravenous bisphosphonates for postmenopausal osteoporosis

  2010cites this paper
• Efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis in children with autoimmune diseases

  2008cites this paper
• Bisphosphonate nephrotoxicity.

  2008cites this paper
• Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates?

  2007cites this paper
• Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate.

  2007cites this paper
• Injectable Bisphosphonates for the Treatment of Osteoporosis

  2007cites this paper
• Tolerability of intravenous pamidronate for the treatment of osteoporosis and other metabolic osteopathies: A retrospective analysis.

  2007cites this paper
• Intermittent Bisphosphonate Therapy in Postmenopausal Osteoporosis

  2007cites this paper
• Use of intravenous bisphosphonates in osteoporosis

  2007cites this paper
• Renal safety of intravenous bisphosphonates in the treatment of osteoporosis

  2007cites this paper
• Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate

  2007cites this paper
• Chapter 18 – Bisphosphonates in the Prevention and Treatment of Postmenopausal Osteoporosis

  2006cites this paper
• NCCN Task Force Report: Bone Health and Cancer Care.

  2006cites this paper
• Cancer-treatment-induced bone loss, part 2.

  2006cites this paper
• Role of oral pamidronate in preventing bone loss in postmenopausal women

  2005cites this paper
• Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years

  2005cites this paper
• Comparison of Intravenous Pamidronate to Standard Therapy for Osteoporosis: Use in Patients Unable to Take Oral Bisphosphonates

  2005cites this paper
• Cancer treatment-induced bone loss in patients with breast or prostate cancer.

  2005cites this paper
• The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by45ca kinetics in the intact rat

  2005cites this paper
• The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis

  2005cites this paper
• Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.

  2005cites this paper
• Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis

  2005cites this paper
• Retrobulbar optic neuritis after pamidronate administration in a patient with a history of cutaneous porphyria

  2005cites this paper
• Bisphosphonate-associated Scleritis: A Case Report and Review

  2005cites this paper
• Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.

  2005cites this paper
• Papel del flúor en la osteoporosis

  2004cites this paper
• Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis

  2004cites this paper
• Intravenous bisphosphonate therapy for osteoporosis: Where do we stand?

  2004cites this paper
• Potential benefits of intermittent bisphosphonate therapy in osteoporosis.

  2004cites this paper
• Effect of pamidronate on new vertebral fractures and bone mineral density in patients with malignant lymphoma receiving chemotherapy.

  2004cites this paper
• New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate.

  2004cites this paper
• Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.

  2004cites this paper
• Intérêt potentiel de l'administration intermittente de bisphosphonate dans le traitement de l'ostéoporosePotential benefits of intermittent bisphosphonate therapy in osteoporosis

  2004cites this paper
• Skeletal Fragility in the Elderly

  2003cites this paper
• Long term effects of a single dose of intravenous Ibandronate.

  2003cites this paper
• A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease

  2003cites this paper
• Highlights from the 98th annual meeting of the American Urological Association Chicago, IL.

  2003cites this paper
• Selected therapy-related clinical research topics in osteoporosis.

  2003cites this paper
• Effects of ibandronate on inflammation in mouse antigen-induced arthritis

  2003cites this paper
• Bisphosphonates to Prevent Osteoporosis in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

  2003cites this paper
• Intravenous ibandronate in men with osteoporosis: An open pilot study over 2 years

  2003cites this paper
• Response to alendronate in osteoporotic women previously treated with pamidronate.

  2003cites this paper
• Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis

  2003cites this paper
• Injectable bisphosphonates in the treatment of postmenopausal osteoporosis

  2003cites this paper
• Bisphosphonates for the Treatment of Osteoporosis

  2003cites this paper
• The effects of three-month intravenous ibandronate on bone mineral density and bone remodeling in Klinefelter's syndrome: the influence of vitamin D deficiency and hormonal status.

  2003cites this paper
• Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys.

  2003cites this paper
• Therapie der Osteoporose

  2003cites this paper
• Effect of cyclical intravenous clodronate therapy on bone mineral density and markers of bone turnover in patients receiving home parenteral nutrition.

  2002cites this paper
• Daily Oral Pamidronate in Women and Men With Osteoporosis: A 3‐Year Randomized Placebo‐Controlled Clinical Trial With a 2‐Year Open Extension

  2002cites this paper
• Bisphosphonates for prevention of postmenopausal osteoporosis.

  2002cites this paper
• Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety

  2002cites this paper
• Intravenous zoledronic acid in postmenopausal women with low bone mineral density.

  2002cites this paper
• Osteoporosis and Diabetes

  2002cites this paper
• [Rational and cost effective osteoporosis prevention and therapy].

  2002cites this paper
• Update on alendronate for osteoporosis: once-weekly dosing

  2001cites this paper
• [Therapy of osteoporosis from the viewpoint of evidence-based medicine].

  2001cites this paper
• Bisphosphonates for osteoporosis in people with cystic fibrosis.

  2001cites this paper
• Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.

  2001cites this paper
• Fragility Fractures in Dialysis and Transplant Patients. Is it Osteoporosis, and how should it be Treated?

  2001cites this paper
• [Glucocorticoid-induced osteoporosis].

  2001cites this paper
• Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis.

  2000cites this paper
• Osteoporosis due to cancer treatment: pathogenesis and management.

  2000cites this paper
• Weekly administration of alendronate: rationale and plan for clinical assessment.

  2000cites this paper
• Effect of First Treatment with Aminobisphosphonates Pamidronate and Ibandronate on Circulating Lymphocyte Subpopulations

  2000cites this paper
• Intermittent and Continuous Administration of the Bisphosphonate Ibandronate in Ovariohysterectomized Beagle Dogs: Effects on Bone Morphometry and Mineral Properties

  1999cites this paper
• The Effectiveness of Cyclic and Continuous Oral Clodronate Therapy on Bone Density and Markers in Osteopenic Postmenopausal Women

  1999cites this paper
• New Bisphosphonates in the Treatment of Bone Diseases

  1999cites this paper
• Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate.

  1998cites this paper
• Osteoporosis in adults with cystic fibrosis

  1998cites this paper
• [Treatment of post menopausal osteoporosis with intravenous pamidronate in patients with esophagogastric pathology].

  1998cites this paper
• The prevention and treatment of osteoporosis.

  1998cites this paper
• Quantitative Bone Mineral Assessment at the Forearm: A Review

  1998cites this paper
• Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis.

  1998cites this paper
• Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.

  1997cites this paper
• A 2-Year Phase II Study with 1-Year of Follow-up of Risedronate (NE-58095) in Postmenopausal Osteoporosis

  1997cites this paper
• The management of osteoporosis.

  1997cites this paper
• Bisphosphonate therapy.

  1997cites this paper
• Ibandronate in oncology

  1997cites this paper
• Bisphosphonates: Mechanisms of Action and Clinical Use in Osteoporosis - An Update

  1997cites this paper
• Bisphosphonates in the treatment of osteoporosis

  1997cites this paper
• Bisphosphonates: preclinical aspects and use in osteoporosis.

  1997cites this paper
• Use of bisphosphonates in cancer patients.

  1996cites this paper
• Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection

  1996cites this paper
• Cyclical pamidronate infusions in postmenopausal osteoporosis.

  1996cites this paper
• A survey of dual‐energy X‐ray absorptiometry (DEXA) normal reference ranges used within the UK and their effect on patient classification

  1995cites this paper
• Ototoxicity associated with intravenous bisphosphonate administration

  1995cites this paper
• Dual energy X-ray absorptiometry normal reference range use within the UK and the effect of different normal ranges on the assessment of bone density.

  1995cites this paper
• THE USE OF BISPHOSPHONATES IN OSTEOPOROSIS

  1994cites this paper